Table 3 The Surveillance, Epidemiology, and End Results (SEER) staging of cancer in SLE patients (n = 10,013)
Stage | N (%) | Incidence rate per 10,000 (n/PYs)a | 95% CI |
|---|---|---|---|
All cancer | 368 (100.0) | 59.07 | (53.04 –65.11) |
 Localized | 187 (50.8) | 30.02 | (25.71 –34.32) |
 Regional | 104 (28.3) | 16.69 | (13.49 –19.90) |
 Distant | 43 (11.7) | 6.90 | (4.84–8.97) |
 Unknown | 34 (9.2) | 5.46 | (3.62–7.29) |
Solid cancer | 337 (100.0) | 54.09 | (48.32–59.87) |
 Localized | 176 (52.2) | 28.25 | (24.08–32.42) |
 Regional | 100 (29.7) | 16.05 | (12.91–19.20) |
 Distant | 30 (8.9) | 4.82 | (3.09–6.54) |
 Unknown | 31 (9.2) | 4.98 | (3.22–6.73) |
Hematologic cancer | 36 (100.0) | 5.78 | (3.89–7.67) |
 Localized | 14 (38.9) | 2.25 | (1.07–3.42) |
 Regional | 4 (11.1) | 0.64 | (0.01–1.27) |
 Distant | 14 (38.9) | 2.25 | (1.07–3.42) |
 Unknown | 4 (11.1) | 0.64 | (0.01–1.27) |